However, subsequent studies of selected patients with HCMS7.4-34,S7.4-35 were unable to establish a clinically useful relation between genotype and SCD risk. In some cases, the rate of adverse events (and prevalence of associated SCD risk factors) was lower in patients with mutations initially felt to be malignant than it was in those with mutations believed to be CLINICAL STATEMENTS AND GUIDELINES Data from series of unselected consecutive outpatients suggest that most mutations are novel and limited to particular Therefore, routine mutation screening would appear to be of little prognostic value in HCM.S7.4-52 The short-term risk of sud- den death in patients who are genotype positive but have no other manifestations of the disease appears to be low.S7.4-53 Therefore, an ICD is not indicated in these individuals. Recommendations for Myocarditis References that support the recommendations are summarized in Online Data Supplement 32. COR LOE Recommendations I C-LD In patients with life-threatening VT or VF associated with confirmed or clinically suspected myocarditis, referral to centers with mechanical hemodynamic support and advanced arrhythmia management is IIb C-LD In patients with giant cell myocarditis with VF or hemodynamically unstable VT treated according to GDMT, an ICD and/or an antiarrhythmic medication may be considered if meaningful survival of greater than 1 year Recommendation-Specific Supportive Text 1. 